Vienna
,
Austria
12 - 15 October 2024
The congress symposium is no longer available
United European Gastroenterology Week (UEG 2024)
Presentation materials
Saturday, 12 October 2024
POSTER
Cardiovascular disease burden in patients with and without metabolic dysfunction-associated steatohepatitis: Data from the unCoVer-MASH longitudinal cohort study
Elisabetta Bugianesi1; Anurag Mehta2; Kamal Kant Mangla3; Abhishek Shankar Chandramouli4; Katrine Grau3; Niels Krarup3; Ahsan Shoeb Patel3; Kwabena Opuni3*
MATERIALS AVAILABLE
Monday, 14 October 2024
ORAL PRESENTATION
Treatment monitoring with the Agile 3+ score in patients with non-alcoholic steatohepatitis: analysis of data from a randomised placebo-controlled trial of semaglutide
Laurent Castéra1; Céline Fournier-Poizat2; Julie Foucquier2; Mette Skalshøi Kjær3; Niels Krarup3; Véronique Miette2; Sune Boris Nygård3; Ahsan Shoeb Patel3; Laurent Sandrin2; Jörn M. Schattenberg4
MATERIALS AVAILABLE
ORAL PRESENTATION
Semaglutide achieves resolution of metabolic dysfunction-associated steatohepatitis via modulation of multiple pathogenic pathways: insights from human and animal studies
Maximilian Jara 1; Jenny Norlin2; Mette S Kjær1; Kasper Almholt2; Kristian M Bendtsen2; Elisabetta Bugianesi3; Kenneth Cusi4; Elisabeth D Galsgaard2; Milan Geybels5; Lise L Gluud6; Lea M Harder2; Rohit Loomba7; Gianluca Mazzoni2; Philip N Newsome 8,9; Louise M Nitze 1; Mads S Palle5; Vlad Ratziu10; Anne-Sophie Sejling 1; Vincent Wong11; Quentin Anstee12,13; Lotte B Knudsen2
MATERIALS AVAILABLE
POSTER
Phase 3 ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: Baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests
Philip N. Newsome1,2; Elisabetta Bugianesi3; Vlad Ratziu4; Mary E. Rinella5; Michael Roden6,7,8*; Kristiane A. Engebretsen9; Iris Kliers9; Laura Harms Østergaard9; Denise Vanni9; Jeppe Zacho9; Arun J. Sanyal10
MATERIALS AVAILABLE
Tuesday, 15 October 2024
POSTER
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic parameters in individuals with metabolic dysfunction-associated steatotic liver disease
Anne-Sophie Sejling1; Matthew J. Armstrong2; Takeshi Okanoue3; Mads Sundby Palle1; Mohamed Tawfik1; Michael Roden4 ; Kwabena Opuni1*
MATERIALS AVAILABLE
POSTER
Safety profile of semaglutide in patients with metabolic dysfunction-associated steatohepatitis: post-hoc analysis of data from two phase 2 studies
Lise Lotte Gluud1; Stephen A. Harrison2; Maximilian Kurt Jara3; Mette Skalshøi Kjær4; Amine Lotfi4; Karina Phonekeo4; Mads Sundby Palle4; Philip N. Newsome5; Kwabena Opuni4*
MATERIALS AVAILABLE
POSTER
Semaglutide improves cardiovascular outcomes in patients with risk of fibrotic MASH - a subgroup analysis from the SELECT trial
Sebastian M. Meyhöfer1,2; Bertrand Cariou3; Cintia Cercato4; Helen Colhoun5; Anne Katrine Duun-Henriksen6; Iris Kliers6; A. Michael Lincoff7; Ildiko Lingvay8; Michelle T. Long6,9; Philip N. Newsome10; Stephen Nicholls11; Maria Quiroga6; Ferruccio Santini12; Arun J. Sanyal13; Steven Kahn14; Bernhard Ludvik15*
MATERIALS AVAILABLE
Keywords